November 2023
1. RAFII MS, Fortea J
   Down Syndrome in a New Era for Alzheimer Disease.
   JAMA. 2023 Nov 22. doi: 10.1001/jama.2023.22924.
   

   >> Share

   
   September 2023
2. RUBIN R
   Who Should-and Can-Get Lecanemab, the New Alzheimer Disease Drug?
   JAMA. 2023 Sep 27. doi: 10.1001/jama.2023.14443.
   

   >> Share

   
   
3. ODOUARD IC, Socal MP, Anderson GF
   Role of Registries in Medicare Coverage of New Alzheimer Disease Drugs.
   JAMA. 2023 Sep 27. doi: 10.1001/jama.2023.17131.
   

   >> Share

   
   
4. RUBIN R
   Consumers Can Now Buy a Blood Test to Evaluate Their Alzheimer Disease Risk, but Should They?
   JAMA. 2023 Sep 13. doi: 10.1001/jama.2023.17685.
   

   >> Share

   
   August 2023
5. HARRIS E
   Study: Identifying Lewy Body Disease Before Symptoms.
   JAMA. 2023;330:686.
   

   >> Share

   
   July 2023
6. HARRIS E
   MIND Diet No Better Than Control for Adults at Risk of Dementia.
   JAMA. 2023 Jul 26. doi: 10.1001/jama.2023.13134.
   

   >> Share

   
   
7. HARRIS E
   Alzheimer Drug Lecanemab Gains Traditional FDA Approval.
   JAMA. 2023 Jul 19. doi: 10.1001/jama.2023.12548.
   

   >> Share

   
   
8. SIMS JR, Zimmer JA, Evans CD, Lu M, et al
   Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.
   JAMA. 2023 Jul 17:e2313239. doi: 10.1001/jama.2023.13239.
   

   >> Share

   
   
9. ROSENTHAL MB
   Novel Alzheimer Disease Treatments and Reconsideration of US Pharmaceutical Reimbursement Policy.
   JAMA. 2023 Jul 17. doi: 10.1001/jama.2023.11702.
   

   >> Share

   
   
10. MANLY JJ, Deters KD
    Donanemab for Alzheimer Disease-Who Benefits and Who Is Harmed?
    JAMA. 2023 Jul 17. doi: 10.1001/jama.2023.11704.
    

    >> Share

    
    
11. RABINOVICI GD, La Joie R
    Amyloid-Targeting Monoclonal Antibodies for Alzheimer Disease.
    JAMA. 2023 Jul 17. doi: 10.1001/jama.2023.11703.
    

    >> Share

    
    
12. WIDERA EW, Brangman SA, Chin NA
    Ushering in a New Era of Alzheimer Disease Therapy.
    JAMA. 2023 Jul 17. doi: 10.1001/jama.2023.11701.
    

    >> Share

    
    
13. HARRIS E
    More Lean Muscle Might Reduce Alzheimer Disease Risk.
    JAMA. 2023 Jul 12. doi: 10.1001/jama.2023.12544.
    

    >> Share

    
    June 2023
14. HARRIS E
    CMS Will Cover Alzheimer Drugs With Traditional FDA Approval.
    JAMA. 2023 Jun 14. doi: 10.1001/jama.2023.10400.
    

    >> Share

    
    
15. HARRIS E
    Brain Cell Biomarker for Preclinical Alzheimer Disease Identified.
    JAMA. 2023 Jun 7. doi: 10.1001/jama.2023.9928.
    

    >> Share

    
    May 2023
16. HARRIS E
    FDA Greenlights First Drug for Agitation Related to Alzheimer Disease.
    JAMA. 2023 May 24. doi: 10.1001/jama.2023.9153.
    

    >> Share

    
    
17. MARCUS R
    New Alzheimer Disease Drugs, Long COVID and the Central Nervous System, and a Nasal Spray for Migraines-Highlights From the 2023 American Academy of Neurology Conference.
    JAMA. 2023 May 10. doi: 10.1001/jama.2023.4389.
    

    >> Share

    
    March 2023
18. HARRIS E
    Blood Biomarker Helps Distinguish Vascular Dementia.
    JAMA. 2023;329:969.
    

    >> Share

    
    February 2023
19. HARRIS E
    Healthful Lifestyle May Slow Memory Loss, Even for APOE Gene Carriers.
    JAMA. 2023;329:622.
    

    >> Share

    
    
20. LE GUEN Y, Raulin AC, Logue MW, Sherva R, et al
    Association of African Ancestry-Specific APOE Missense Variant R145C With Risk of Alzheimer Disease.
    JAMA. 2023;329:551-560.
    

    >> Share

    
    January 2023
21. LARKIN HD
    Lecanemab Gains FDA Approval for Early Alzheimer Disease.
    JAMA. 2023 Jan 18. doi: 10.1001/jama.2022.24490.
    

    >> Share

    
    
22. LARKIN H
    Noninvasive Sensory Stimulation With Light and Sound Tested in Alzheimer Disease.
    JAMA. 2023;329:114.
    

    >> Share

    
    September 2022
23. HARRIS E
    Large Autopsy Study Estimates Prevalence of "LATE" Neuropathologic Change.
    JAMA. 2022;328:815-816.
    

    >> Share

    
    August 2022
24. RUBIN R
    Much Anticipated Alzheimer Disease Prevention Trial Finds No Clinical Benefit From Drug Targeting Amyloid; Highlights Need to Consider Other Approaches.
    JAMA. 2022 Aug 17. pii: 2795592. doi: 10.1001/jama.2022.11490.
    

    >> Share

    
    
25. DEPEW R
    To My Husband With Alzheimer Disease.
    JAMA. 2022;328:587.
    

    >> Share

    
    
26. SLOMSKI A
    Anti-Tau Antibody Semorinemab Fails to Slow Alzheimer Disease.
    JAMA. 2022;328:415.
    

    >> Share

    
    July 2022
27. SURAN M
    Some Antioxidants May Mitigate the Risk of Dementias.
    JAMA. 2022;328:321.
    

    >> Share

    
    June 2022
28. RUBIN R
    New Test to Help Diagnose Alzheimer Disease.
    JAMA. 2022;327:2281.
    

    >> Share

    
    May 2022
29. LARKIN HD
    First Donepezil Transdermal Patch Approved for Alzheimer Disease.
    JAMA. 2022;327:1642.
    

    >> Share

    
    December 2021
30. SLOMSKI A
    Methylphenidate Treats Apathy in Alzheimer Disease.
    JAMA. 2021;326:2120.
    

    >> Share

    
    October 2021
31. EMANUEL EJ
    A Middle Ground for Accelerated Drug Approval-Lessons From Aducanumab.
    JAMA. 2021;326:1367-1368.
    

    >> Share

    
    September 2021
32. ANDERSON TS, Ayanian JZ, Souza J, Landon BE, et al
    Representativeness of Participants Eligible to Be Enrolled in Clinical Trials of Aducanumab for Alzheimer Disease Compared With Medicare Beneficiaries With Alzheimer Disease and Mild Cognitive Impairment.
    JAMA. 2021 Sep 9. pii: 2784225. doi: 10.1001/jama.2021.15286.
    

    >> Share

    
    August 2021
33. RUBIN R
    CMS Considers Controversial Alzheimer Drug Coverage.
    JAMA. 2021;326:690.
    

    >> Share

    
    July 2021
34. RUBIN R
    Recently Approved Alzheimer Drug Raises Questions That Might Never Be Answered.
    JAMA. 2021 Jul 21. pii: 2782427. doi: 10.1001/jama.2021.11558.
    

    >> Share

    
    
35. SCHULMAN KA, Greicius MD, Richman B
    Will CMS Find Aducanumab Reasonable and Necessary for Alzheimer Disease After FDA Approval?
    JAMA. 2021 Jul 19. pii: 2782333. doi: 10.1001/jama.2021.11768.
    

    >> Share

    
    June 2021
36. CHEN MH, Yang FC, Liang CS
    APOE Allele Testing and Alzheimer Disease.
    JAMA. 2021;325:2210-2211.
    

    >> Share

    
    
37. CHOUDHURY P, Ramanan VK, Boeve BF
    APOE Allele Testing and Alzheimer Disease-Reply.
    JAMA. 2021;325:2211.
    

    >> Share

    
    April 2021
38. RUBIN R
    Neurologist Faces His Alzheimer Diagnosis Determined to Lessen Stigma Surrounding the Disease.
    JAMA. 2021 Apr 28. pii: 2779452. doi: 10.1001/jama.2021.5333.
    

    >> Share

    
    March 2021
39. ALEXANDER GC, Emerson S, Kesselheim AS
    Evaluation of Aducanumab for Alzheimer Disease: Scientific Evidence and Regulatory Review Involving Efficacy, Safety, and Futility.
    JAMA. 2021 Mar 30. pii: 2778191. doi: 10.1001/jama.2021.3854.
    

    >> Share

    
    January 2021
40. CHOUDHURY P, Ramanan VK, Boeve BF
    APOE varepsilon4 Allele Testing and Risk of Alzheimer Disease.
    JAMA. 2021 Jan 14. pii: 2775399. doi: 10.1001/jama.2020.15085.
    

    >> Share

    
    November 2020
41. MADDOX M
    Alzheimer Aubade.
    JAMA. 2020;324:2108.
    

    >> Share

    
    October 2020
42. TSOU AY, Bulova P, Capone G, Chicoine B, et al
    Medical Care of Adults With Down Syndrome: A Clinical Guideline.
    JAMA. 2020;324:1543-1556.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share